Shorter treatment course potentially on the horizon for hep C patients

Saturday, April 16, 2016 - 03:02 in Health & Medicine

Data from a Phase 2 clinical trial show that an investigational injectable treatment known as RG-101 in combination with a four week course of oral direct-acting antiviral (DAA) treatment was well tolerated and resulted in high virologic response rates post-treatment among hepatitis C (HCV) infected patients with genotypes 1 and 4, who had not been treated previously.

Read the whole article on Science Daily

More from Science Daily

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net